PET imaging of CD105/endoglin expression with a 61/64Cu-labeled Fab antibody fragment

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 5, 2013, Pages 759-767

  Zhang, Yin ^a   Hong, Hao ^b   Orbay, Hakan ^b   Valdovinos, Hector F ^a   Nayak, Tapas R ^b   Theuer, Charles P ^c   Barnhart, Todd E ^a   Cai, Weibo ^a,b,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c TRACON Pharmaceuticals Inc   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Antibody fragment; CD105(endoglin); Fab; Positron emission tomography (PET); Tumor angiogenesis

Indexed keywords

(1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID) TRC 105 CU 61; (1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID) TRC 105 CU 64; ENDOGLIN; PAPAIN; TRACER; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; COPPER; ENG PROTEIN, HUMAN; IMMUNOGLOBULIN F(AB) FRAGMENT; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TRC105; DIAGNOSTIC AGENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BREAST CANCER; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG PURITY; DRUG SPECIFICITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; PET-CT SCANNER; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; EXPERIMENTAL MAMMARY NEOPLASM; GENE EXPRESSION REGULATION; ISOTOPE LABELING; MCF 7 CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PROCEDURES; RADIOMETRY; SCINTISCANNING; VASCULARIZATION; CELL STRAIN MCF 7; METHODOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; COPPER RADIOISOTOPES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; ISOTOPE LABELING; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RECEPTORS, CELL SURFACE;

EID: 84888166523     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2334-2     Document Type: Article

References (45)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-57.
2. Backer MV, Backer JM. Imaging key biomarkers of tumor angiogenesis. Theranostics. 2012;2:502-15.
3. Dijkgraaf I, Boerman OC. Radionuclide imaging of tumor angiogenesis. Cancer Biother Radiopharm. 2009;24:637-47.
4. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008;49 Suppl 2:113S-28S.
5. Cai W, Rao J, Gambhir SS, Chen X. How molecular imaging is speeding up anti-angiogenic drug development. Mol Cancer Ther. 2006;5:2624-33.
6. Backer MV, Levashova Z, Patel V, Jehning BT, Claffey K, Blankenberg FG, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med. 2007;13:504-9.
7. Cai W, Niu G, Chen X. Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des. 2008;14:2943-73.
8. Zhang Y, Yang Y, Hong H, Cai W. Multimodality molecular imaging of CD105 (Endoglin) expression. Int J Clin Exp Med. 2011;4:32-42.
9. Cai W, Chen X. Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci. 2007;12:4267-79.
10. Wang RE, Niu Y, Wu H, Amin MN, Cai J. Development of NGR peptide-based agents for tumor imaging. Am J Nucl Med Mol Imaging. 2011;1:36-46.
11. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14:1931-7.
12. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res. 2010;86:12-9.
13. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011;38:1335-43.
14. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, et al. A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin Cancer Res. 2012;18:4820-9.
15. Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 2008;14:191-7.
16. Andrew SM, Pimm MV, Perkins AC, Baldwin RW. Comparative imaging and biodistribution studies with an anti-CEA monoclonal antibody and its F(ab)2 and Fab fragments in mice with colon carcinoma xenografts. Eur J Nucl Med. 1986;12:168-75.
17. Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E, et al. PET of hypoxia with 89Zr-labeled cG250-F (ab')2 in head and neck tumors. J Nucl Med. 2010;51:1076-83.
18. Leyton JV, Olafsen T, Lepin EJ, Hahm S, Bauer KB, Reiter RE, et al. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res. 2008;14:7488-96.
19. Cai W, Olafsen T, Zhang X, Cao Q, Gambhir SS, Williams LE, et al. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med. 2007;48:304-10.
20. Olafsen T, Sirk SJ, Olma S, Shen CK, Wu AM. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biol. 2012;33:669-77.
21. Griffiths GL, Goldenberg DM, Roesch F, Hansen HJ. Radiolabeling of an anti-carcinoembryonic antigen antibody Fab' fragment (CEAScan) with the positron-emitting radionuclide Tc-94m. Clin Cancer Res. 1999;5:3001s-3s.
22. Yoshida C, Tsuji AB, Sudo H, Sugyo A, Sogawa C, Inubushi M, et al. Development of positron emission tomography probe of 64Culabeled anti-C-kit 12A8 Fab to measure protooncogene C-kit expression. Nucl Med Biol. 2011;38:331-7.
23. Burvenich IJ, Schoonooghe S, Blanckaert P, Bacher K, Vervoort L, Coene E, et al. Biodistribution and planar gamma camera imaging of 123I- and 131I-labeled F(ab')2 and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor. Nucl Med Biol. 2007;34:257-65.
24. Brouwers A, Mulders P, Oosterwijk E, BuijsW, Corstens F, Boerman O, et al. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. Cancer Biother Radiopharm. 2004;19:466-77.
25. Sandstrom K, Haylock AK, Spiegelberg D, Qvarnstrom F, Wester K, Nestor M. A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio. Int J Oncol. 2012;40:1525-32.
26. Rousseaux J, Rousseaux-Prevost R, Bazin H. Optimal conditions for the preparation of Fab and F(ab')2 fragments from monoclonal IgG of different rat IgG subclasses. J Immunol Methods. 1983;64:141-6.
27. Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, Barnhart TE, et al. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging. 2012;39:138-48.
28. Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR, et al. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res. 2000;6:2037-43.
29. Zhang Y, Hong H, Engle JW, Yang Y, Theuer CP, Barnhart TE, et al. Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody. Mol Pharm. 2012;9:645-53.
30. Zhang Y, Hong H, Engle JW, Yang Y, Barnhart TE, Cai W. Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am J Nucl Med Mol Imaging. 2012;2:1-13.
31. Zhang Y, Hong H, Severin GW, Engle JW, Yang Y, Goel S, et al. ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. Am J Transl Res. 2012;4:333-46.
32. Dearling JLJ, Voss SD, Dunning P, Snay E, Fahey F, Smith SV, et al. Imaging cancer using PET - the effect of the bifunctional chelator on the biodistribution of a 64Cu-labeled antibody. Nucl Med Biol. 2011;38:29-38.
33. Hong H, Benink HA, Zhang Y, Yang Y, Uyeda HT, Engle JW, et al. HaloTag: a novel reporter gene for positron emission tomography. Am J Transl Res. 2011;3:392-403.
34. Zhang Y, Hong H, Engle JW, Bean J, Yang Y, Leigh BR, et al. Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One. 2011;6:e28005.
35. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137-46.
36. Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, et al. Endoglin-targeted cancer therapy. Curr Drug Deliv. 2011;8:135-43.
37. Hong H, Zhang Y, Severin GW, Yang Y, Engle JW, Niu G, et al. Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. Mol Pharm. 2012;9:2339-49.
38. Grassi I, Nanni C, Allegri V, Morigi JJ, Montini GC, Castellucci P, et al. The clinical use of PET with 11C-acetate. Am J Nucl Med Mol Imaging. 2012;2:33-47.
39. Vach W, Høilund-Carlsen PF, Fischer BM, Gerke O, Weber W. How to study optimal timing of PET/CT for monitoring of cancer treatment. Am J Nucl Med Mol Imaging. 2011;1:54-62.
40. Alauddin MM. Positron emission tomography (PET) imaging with 18F-based radiotracers. Am J Nucl Med Mol Imaging. 2012;2:55-76.
41. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275-90.
42. Costello B, Li C, Duff S, Butterworth D, Khan A, Perkins M, et al. Perfusion of 99mTc-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int J Cancer. 2004;109:436-41.
43. Williams HA, Robinson S, Julyan P, Zweit J, Hastings D. A comparison of PET imaging characteristics of various copper radioisotopes. Eur J Nucl Med Mol Imaging. 2005;32:1473-80.
44. Tsujie M, Uneda S, Tsai H, Seon BK. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites. Int J Oncol. 2006;29:1087-94.
45. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res. 1999;5:371-82.